Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Jäger, Wolfgang ^a,b   Moskalev, Igor ^a   Janssen, Claudia ^a,b   Hayashi, Tetsutaro ^a   Awrey, Shannon ^a   Gust, Kilian M ^a,c   So, Alan I ^a   Zhang, Kaixin ^a   Fazli, Ladan ^a   Li, Estelle ^a   Thüroff, Joachim W ^b   Lange, Dirk ^a   Black, Peter C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; ONCOLYTIC VIRUS;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG UPTAKE; ECHOGRAPHY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; REPRODUCIBILITY; SYSTEMIC THERAPY; TUMOR XENOGRAFT; ULTRASOUND GUIDED PERCUTANEOUS TUMOR INOCULATION; ULTRASOUND SCANNER;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEASIBILITY STUDIES; FEMALE; HUMANS; MICE; ONCOLYTIC VIRUSES; SURGERY, COMPUTER-ASSISTED; TRANSPLANTATION, HETEROLOGOUS; ULTRASONICS; URINARY BLADDER NEOPLASMS;

ANIMALIA; MUS; MUS MUSCULUS; VESICULAR STOMATITIS VIRUS;

EID: 84875449957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059536     Document Type: Article

References (30)

1. Ploeg M, Aben KK, Kiemeney LA, (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293.
2. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin. 62: 10-29.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, et al. (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997-1008.
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-477.
5. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, et al. (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. J Urol 176: 2414-2422.
6. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608.
7. Chan E, Patel A, Heston W, Larchian W, (2009) Mouse orthotopic models for bladder cancer research. BJU Int 104: 1286-1291.
8. Kubota T, (1994) Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem 56: 4-8.
9. Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, et al. (2007) A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int 100: 1377-1384.
10. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, et al. (1995) Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 154: 1532-1538.
11. Summerhayes IC, Franks LM, (1979) Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 62: 1017-1023.
12. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR, (1999) Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 5914: 3512-3517.
13. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, et al. (1999) Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81: 638-646.
14. Iinuma S, Bachor R, Flotte T, Hasan T, (1995) Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model. J Urol 153: 802-806.
15. Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, et al. (2013) Hiding in plain view: Genetic profiling reveals decades old cross-contamination of bladder cancer cell line KU7 with HeLa. J Urol: in press.
16. Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD, (2000) Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 7: 844-851.
17. Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, et al. (2010) Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int 106: 1799-1804.
18. Patel AR, Chan ES, Hansel DE, Powell CT, Heston WD, et al. (2010) Transabdominal micro-ultrasound imaging of bladder cancer in a mouse model: a validation study. Urology 75: 799-804.
19. Rychak JJ, Graba J, Cheung AM, Mystry BS, Lindner JR, et al. (2007) Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging 6: 289-296.
20. Grossman HB, Wedemeyer G, Ren L, (1984) UM-UC-1 and UM-UC-2: characterization of two new human transitional cell carcinoma lines. J Urol 132: 834-837.
21. Grossman HB, Wedemeyer G, Ren L, Wilson GN, Cox B, (1986) Improved growth of human urothelial carcinoma cell cultures. J Urol 136: 953-959.
22. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, et al. (2006) Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 175: 1133-1137.
23. Choi W, Shah JB, Tran M, Svatek R, Marquis L, et al. (2012) p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. PLoS ONE 7(1): e30206.
24. Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D, (2011) Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A. 108: 1275-1284.
25. American Joint Committee on Cancer (2010) AJCC cancer staging manual. Springer, New York London.
26. Klerk CP, Overmeer RM, Niers TM, Versteeg HH, Richel DJ, et al. (2007) Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 43: 7-13.
27. Adam L, Black PC, Kassouf W, Eve B, McConkey D, et al. (2007) Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol 177: 1900-1906.
28. Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, et al. (2011) Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel. Invest Radiol 46: 441-449.
29. Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, et al. (2012) Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther 19: 374-381.
30. Cheon J, Moon DG, Cho HY, Park HS, Kim JJ, et al. (2002) Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model. Int J Urol 9: 261-267.